Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update

- IMO-2125 Confirmed Responses in PD-1 Refractory Melanoma Appear Durable - - First Third… Read more 

Idera to Present at the 37th Annual Cowen and Company Health Care Conference

CAMBRIDGE, Mass. and EXTON, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Results Demonstrate IMO-2125 plus ipilimumab combination is tolerable at all dose levels studied… Read more 

Learn More


Fri, 24 Mar 2017 16:36:54 GMT

Idera Pharmaceuticals, Inc. Calendar Events

A Collection of Idera Pharmaceuticals, Inc. Calendar Events… Read more 

Learn More